CYTK:NSD-Cytokinetics Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 56.68

Change

+0.97 (+1.74)%

Market Cap

USD 6.16B

Volume

1.19M

Analyst Target

USD 40.25
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+1.76 (+0.39%)

USD 119.56B
REGN Regeneron Pharmaceuticals Inc

-1.77 (-0.17%)

USD 114.65B
ALNY Alnylam Pharmaceuticals Inc

-1.54 (-0.57%)

USD 34.86B
ARGX argenx NV ADR

-13.04 (-2.40%)

USD 32.89B
MRNA Moderna Inc

-0.87 (-1.42%)

USD 25.27B
BGNE BeiGene Ltd

+12.40 (+5.31%)

USD 24.38B
RPRX Royalty Pharma Plc

N/A

USD 16.72B
UTHR United Therapeutics Corporatio..

+5.86 (+1.67%)

USD 15.95B
SMMT Summit Therapeutics PLC

+0.48 (+2.58%)

USD 15.35B
PCVX Vaxcyte Inc

+0.21 (+0.19%)

USD 14.00B

ETFs Containing CYTK

VTWV Vanguard Russell 2000 Val.. 0.43 % 0.20 %

+1.59 (+1.11%)

USD 0.80B
IWN iShares Russell 2000 Valu.. 0.00 % 0.00 %

+2.05 (+1.11%)

N/A
VRTVX Vanguard Scottsdale Funds.. 0.00 % 0.00 %

N/A

USD 0.91B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -32.11% 40% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -32.11% 40% F 24% F
Trailing 12 Months  
Capital Gain 85.23% 83% B 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 85.23% 83% B 91% A-
Trailing 5 Years  
Capital Gain 381.97% 95% A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 381.97% 95% A 96% N/A
Average Annual (5 Year Horizon)  
Capital Gain 50.53% N/A N/A 90% A-
Dividend Return 50.53% N/A N/A 90% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 75.26% N/A N/A 23% F
Risk Adjusted Return 67.14% N/A N/A 87% B+
Market Capitalization 6.16B 96% N/A 90% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector